Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 291 · FY2023 2,264 · FY2024 375 — 3-yr total 2,930
Pharmacy chain/pharmaceuticals distributor operating in Georgia.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 13,790 | 19,785 | 23,780 | 32,208 | 33,896 | 31,577 | 36,614 | +17.7% | |
| Total COGS | 11,656 | 16,906 | 19,303 | 26,678 | 27,014 | 24,981 | 30,610 | +17.5% |
| Gross Profit | 2,135 | 2,879 | 4,477 | 5,531 | 6,882 | 6,597 | 6,003 | +18.8% |
| Gross Margin | 15.5% | 14.6% | 18.8% | 17.2% | 20.3% | 20.9% | 16.4% | |
| 1,144 | 1,275 | 1,756 | 2,597 | 2,927 | 3,325 | 4,017 | +23.3% | |
| EBITDA | 991 | 1,604 | 2,721 | 2,934 | 3,955 | 3,272 | 1,987 | +12.3% |
| EBITDA Margin | 7.2% | 8.1% | 11.4% | 9.1% | 11.7% | 10.4% | 5.4% | |
| Total D&A | 26 | 26 | 26 | 30 | 56 | 88 | 117 | +28.5% |
| EBIT / Operating Income | 965 | 1,578 | 2,695 | 2,904 | 3,899 | 3,184 | 1,870 | +11.7% |
| Total Interest Expense | 30 | 46 | 23 | 0 | 0 | 0 | 2 | -35.3% |
| 0 | 0 | 250 | 39 | 259 | 18 | 101 | nmf | |
| Profit Before Tax | 935 | 1,532 | 2,423 | 2,943 | 4,158 | 3,166 | 1,968 | +13.2% |
| Total Income Tax | 0 | 0 | 0 | 0 | 20 | 400 | 66 | +84.0% |
| Net Profit / (Loss) | 935 | 1,532 | 2,421 | 2,583 | 4,092 | 2,767 | 1,902 | +12.6% |
| Net Margin | 6.8% | 7.7% | 10.2% | 8.0% | 12.1% | 8.8% | 5.2% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →